| Similar Articles |
|---|
 |
The Motley Fool
June 15, 2010
Brian Orelli |
Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.   |
American Journal of Nursing
October 2009 |
Pharmacogenomics: Personalizing Drug Therapy Pharmacogenomics is a rapidly growing field of research into the ways in which genetic variation affects drug response. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
The Motley Fool
May 28, 2010
Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
The Motley Fool
June 2, 2011
Luke Timmerman |
Infinity Dares to Think Big Against Pancreatic Cancer, Prepares to Show Early Results This Weekend Infinity Pharmaceuticals' top execs sometimes get strange looks when they say they are developing a new drug for pancreatic cancer. Is this a smart use of the company's time and resources? |
Managed Care
August 2007
Martin Sipkoff |
Soaring Price of Cancer Drugs Leads Plans To New Approaches Insurers are trying different methods, from pay for performance to promoting preventive care, to hold down cost of chemotherapy drugs. |
The Motley Fool
May 24, 2010
Brian Orelli |
ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
Chemistry World
November 4, 2010
Laura Howes |
Blocking cancer drug's toxic side effects US researchers have identified a compound that could drastically reduce toxic side effects associated with a widely used cancer drug. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
April 7, 2011
Brian Orelli |
Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
Pharmaceutical Executive
October 1, 2010 |
When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve? |
The Motley Fool
February 24, 2011
Brian Orelli |
Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead. |
Nursing Management
June 2009
Zimmerman & Britton |
Prevention Through Vigilance: Malignant Melanoma Management Nurses can play a critical role in the care of patients with melanoma by offering preventive education and support. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Nursing
January 2011
Carl A. Kirton |
HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness. |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Pharmaceutical Executive
November 1, 2012
Lauri Mitchell |
Who Pays for Specialty Medicines? Providers and patients fish for that delicate balance between access and abandonment. |
CRM
July 2013
Leonard Klie |
Drug Makers Are in the Midst of a Digital Revolution Pharmaceutical firms are sharpening their focus on multichannel marketing and analytics. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
Pharmaceutical Executive
September 1, 2012
Robin Hertz |
The Endless Treadmill of End-of-Life Care Bending the cost curve back to valuing the cycle of life. |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
American Family Physician
August 15, 2006
Stump, Mayo & Blum |
Management of Grapefruit-Drug Interactions Grapefruit is a healthy addition to a well-balanced diet. However, the fruit has been shown to affect the metabolism of many medications, increasing the risk of toxicity and adverse effects. |
American Family Physician
November 15, 2002
Cynthia M. Williams |
Using Medications Appropriately in Older Adults Finding the right balance between too few and too many drugs will help ensure increased longevity, improved overall health, and enhanced functioning and quality of life for the aging population. |
Nursing
November 2011
Jeanne Held-Warmkessel |
Taming Three High-Risk Chemotherapy Complications A review of three common chemotherapy-associated complications that can be serious enough to require hospitalization: febrile neutropenia, chemotherapy-related nephrotoxicity, and chemotherapy-related enterotoxicity. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Pharmaceutical Executive
May 1, 2007
Patrick Clinton |
The Topic of Cancer What will tomorrow's cancer commercialization model really look like? We asked four heavyweights from the world of oncology what they thought. |
Nurse Practitioner
February 2011
Jennifer M. Belavic |
Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
Nursing
March 2012
Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
Pharmaceutical Executive
July 1, 2011
Cabacungan & Clark |
New Ways to Gain New Brand Insights If you can learn to understand patient and physician behavior, you are well on your way to strengthening the position of your product. |
The Motley Fool
October 26, 2010
Ralph Casale |
Where We Are in the War on Cancer A summary of the roundtable discussions at Xconomy's recent event, "Boston's War on Cancer." |
Pharmaceutical Executive
August 1, 2012
Debbie Warner |
Adapting to a New Era of Cancer Care Coverage and treatment decisions will be driven by value and defined differently by each stakeholder. |
Chemistry World
March 12, 2013
Anthony King |
Googling for new drug side effects Previously unknown prescription drug side effects have been revealed by the searches people do online. |
Pharmaceutical Executive
June 1, 2014
Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
Pharmaceutical Executive
January 1, 2013
Al Topin |
The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
CIO
September 27, 2013 |
How IT Can Produce Better Patient Care For Dr. Bob Laskowski, president and CEO of Christiana Care Health System, technology means empowering physicians and patients. |
